AzTrials
AzTrials

Geographic AtrophyPhase 3ARCHER IINCT06510816

A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)

A Phase 3 study testing Vonaprument in people with Geographic Atrophy, run by Annexon, Inc. at 132 sites in 14 countries.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

The primary purpose of the study is to determine if IVT injections of vonaprument every month reduce vision loss in participants with dry AMD with GA. Read more about this study

Who is it for?
Ages 50 years and older
Conditions the study is for
Geographic Atrophy
What is being tested?
Vonaprument
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
659 participants
Where
132 sitesin 14 countries
Study dates
30 Jul 2024to 31 Jul 2027
Phase
Phase 3
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 50 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Diagnosis of dry AMD with GA as determined by the Investigator and confirmed by the independent Central Reading Center.

Who cannot join

  • Geographic atrophy due to other causes than AMD such as Stargardt disease, cone-rod dystrophy, pathologic myopia, or toxic maculopathies (for example, plaquenil maculopathy) in either eye.
  • NOTE: Other protocol-defined inclusion and exclusion criteria apply.

Trial locations and contacts

132 sites in 14 countries.

132 sites in 14 countries

United States71 sites

  • Retina Consultants of Hawaii

    ‘Aiea, Hawaii, 96701

  • Retina Research Institute of Texas

    Abilene, Texas, 79606

  • Palmetto Retina Center

    Aiken, South Carolina, 29802

  • Vision Research Center Eye Associates of New Mexico

    Albuquerque, New Mexico, 87109

  • Southwest Retina Specialists

    Amarillo, Texas, 79106

  • Texas Retina Associates- Arlington

    Arlington, Texas, 76012

  • Asheville Eye Associates - Retina Division

    Asheville, North Carolina, 28803

  • Austin Research Center for Retina

    Austin, Texas, 78705

  • Austin Retina Associates

    Austin, Texas, 78705

  • Austin Clinical Research, LLC

    Austin, Texas, 78750

  • Retina Consultants of Charleston

    Beaufort, South Carolina, 29901

  • Retina Consultants of Texas

    Bellaire, Texas, 77401

  • Retina-Vitreous Associates Medical Group

    Beverly Hills, California, 90211

  • Envision Ocular, LLC

    Bloomfield, New Jersey, 07003

  • Ophthalmic Consultants of Boston

    Boston, Massachusetts, 02114

  • North Carolina Retina Associates

    Cary, North Carolina, 27511

  • Charleston Neuroscience Center

    Charleston, South Carolina, 29414

  • Mid Atlantic Retina New Jersey

    Cherry Hill, New Jersey, 08054

  • Retina Group of Washington

    Chevy Chase, Maryland, 20815

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio, 44106

  • Retina Consultants of Southern Colorado PC

    Colorado Springs, Colorado, 80909

  • Retina Foundation of the Southwest

    Dallas, Texas, 75231

  • Texas Retina Associates

    Dallas, Texas, 75231

  • Rand Eye Institute

    Deerfield Beach, Florida, 33064

  • RSC Research, LLC

    Denver, Colorado, 80222

  • Retina Vitreous Center

    Edmond, Oklahoma, 73013

  • Retina Associates Ltd

    Elmhurst, Illinois, 60126

  • Erie Retina Research, LLC

    Erie, Pennsylvania, 16507

  • Verum Research, LLC

    Eugene, Oregon, 97401

  • National Ophthalmic Research Institute

    Fort Myers, Florida, 33912

  • Texas Retina Associates

    Fort Worth, Texas, 76104

  • Retinal Consultants of Orange County Clinical Research Institute Inc

    Fullerton, California, 92835

  • Global Research Management

    Glendale, California, 91204

  • Cumberland Valley Retina Consultants

    Hagerstown, Maryland, 21740

  • Mid Atlantic Retina Specialists

    Hagerstown, Maryland, 21740

  • Long Island Vitreoretinal Consultants

    Hauppauge, New York, 11788

  • Southeastern Retina Associates

    Johnson City, Tennessee, 37604

  • Retina Consultants of Texas

    Katy, Texas, 77494

  • Eye Care Specialists

    Kingston, Pennsylvania, 18704

  • Piedmont Eye Center

    Lynchburg, Virginia, 24502

  • Georgia Retina PC

    Marietta, Georgia, 30060

  • Retina Consultants Medical Group

    Modesto, California, 95356

  • Northern California Retina Vitreous Associates Medical Group, Inc.

    Mountain View, California, 94040

  • Tennessee Retina PC

    Nashville, Texas, 37203

  • University Retina

    Oak Forest, Illinois, 60452

  • Florida Retina Institute

    Orlando, Florida, 32806

  • Fort Lauderdale Eye Institute

    Plantation, Florida, 33324

  • Maine Eye Center

    Portland, Maine, 04101

  • Eyehealth Northwest Portland

    Portland, Oregon, 97209

  • Sierra Eye Associates

    Reno, Nevada, 89502

  • Retinal Consultants Medical Group

    Sacramento, California, 95825

  • Retina Consultants of Minnesota

    Saint Louis Park, Minnesota, 55416

  • Rocky Mountain Retina Consultants

    Salt Lake City, Utah, 84107

  • Retina Consultants of Texas San Antonio

    San Antonio, Texas, 78240

  • Retina Group of Florida

    Sarasota, Florida, 34232

  • Retina Macula Institute of Arizona

    Scottsdale, Arizona, 85255

  • Springfield Clinic LLP

    Springfield, Illinois, 62703

  • Retina Research Institute at New England Retina Consultants

    Springfield, Massachusetts, 01107

  • Cascade Medical Research Institute

    Springfield, Oregon, 97477

  • Retina Vitreous Associates of Florida

    St. Petersburg, Florida, 33711

  • East Florida Eye Institute

    Stuart, Florida, 34994

  • Retina Associates of Florida

    Tampa, Florida, 33609

  • Retina Consultants of Texas

    The Woodlands, Texas, 77384

  • Macula Retina Vitreous Research Institute

    Torrance, California, 90503

  • Tulsa Retina Consultants

    Tulsa, Oklahoma, 74114

  • North Carolina Retina Associates

    Wake Forest, North Carolina, 27587

  • Bay Area Retina Associates

    Walnut Creek, California, 94598

  • Eye Clinic of Wisconsin

    Wausau, Wisconsin, 54403

  • Wolfe Eye Clinic

    West Des Moines, Iowa, 50266

  • Strategic Clinical Research Group, LLC

    Willow Park, Texas, 76087

  • Piedmont Retina Specialists

    Winston-Salem, North Carolina, 27103

Other trials in United States

Spain10 sites

  • Institut Català de Retina

    Barcelona, 08017

  • Hospital Universitari Vall d'Hebron

    Barcelona, 08035

  • Hospital de la Arruzafa - Metavisión Arruzafa

    Córdoba, 14012

  • Clínica Baviera

    Madrid, 28046

  • Hospital Universitario Puerta de Hierro - Majadahonda

    Majadahonda, 28222

  • Hospital Universitari General de Catalunya - Valles Ophthalmology Research - OMIQ Research

    Sant Cugat del Vallès, 08195

  • Hospital Clinico Universitario de Santiago

    Santiago de Compostela, 15706

  • Hospital Universitario Virgen Macarena

    Seville, 41009

  • Oftalvist IMED Burjassot

    Valencia, Burjassot, 46100

  • Hospital Universitario Miguel Servet

    Zaragoza, 50009

Other trials in Spain

France8 sites

  • Groupe Hospitalier Pellegrin - CHU de Bordeaux

    Bordeaux, 33076

  • Centre Hospitalier Intercommunal De Créteil

    Créteil, 94000

  • CHU Dijon Bourgogne - Hôpital François Mitterrand

    Dijon, 21079

  • Centre Ophtalmologique Pôle Vision Val d'Ouest

    Écully

  • Centre Monticelli Paradis d'Ophtalmologie

    Marseille

  • Centre Hospitalier Universitaire de Nice

    Nice, 06001

  • Hôpital Lariboisière - Service d'ophtalmologie

    Paris, 75010

  • Centre Ophtalmologique Maison Rouge

    Strasbourg, 67000

Other trials in France

Italy8 sites

  • Azienda Ospedaliera Universitaria Careggi

    Florence, 50134

  • IRCCS MultiMedica

    Milan, 20123

  • ASST Fatebenefratelli Sacco

    Milan, 20157

  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico

    Milan, 20122

  • IRCCS Ospedale San Raffaele

    Milan, 20132

  • Fondazione G.B. Bietti Per Lo Sudio E La Ricerca In Oftalmologia - Presidio

    Roma, 00184

  • Fondazione PTV Policlinico Tor Vergata

    Rome, 00133

  • Fondazione Policlinico Agostino Gemelli

    Rome, 00168

Other trials in Italy

Australia5 sites

  • Eye Clinic Albury Wodonga

    Albury, New South Wales, 2640

  • Marsden Eye Specialists

    Parramatta, New South Wales, 2150

  • Strathfield Retina Clinic

    Strathfield, New South Wales, 2135

  • Sydney Eye Hospital

    Sydney, New South Wales, 2000

  • Sydney Retina Clinic and Day Surgery

    Sydney, New South Wales, 2000

Other trials in Australia

Germany5 sites

  • Universitäts-Klinikum Bonn

    Bonn, 53127

  • Universitätsklinikum Heidelberg

    Heidelberg, 69120

  • Augenzentrum am St. Franziskus-Hospital

    Münster, North Rhine-Westphalia, 48145

  • Dietrich Bonhoeffer Klinikum Klinik für Augenheilkunde

    Neubrandenburg, Mecklenburg-Vorpommern, 17036

  • Universitätsklinikum Tübingen, Department für Augenheilkunde

    Tübingen, 72076

Other trials in Germany

Hungary5 sites

  • Semmelweis Egyetem

    Budapest, 1085

  • Budapesti Bajcsy-Zsilinszky Kórház és Rendelőintézet Szemészet Osztály

    Budapest, 1106

  • Budapest Retina Associates

    Budapest, 1133

  • Debreceni Egyetem Klinikai Kozpont Nagyerdei Campus

    Debrecen, Hajdú-Bihar, 4032

  • Ganglion Medical Center

    Pécs, Baranya, 7621

Other trials in Hungary

Poland5 sites

  • Oftalmika Sp.Zo.O.

    Bydgoszcz, 85-631

  • Centrum Diagnostyki I Mikrochirurgii Oka Lens Sp. Z O.O.

    Olsztyn, 10-424

  • Ośrodek Chirurgii Oka Prof. Zagórskiego Sp. Z o.o.

    Rzeszów, 35-017

  • Caminomed Sp. Z O.O.

    Tarnowskie Góry, 42-600

  • Warszawski Szpital Okulistyczny

    Warsaw, 01-258

Other trials in Poland

Canada4 sites

  • Calgary Retina Consultants

    Calgary, Alberta, T2H 0C8

  • Alberta Retina Consultants

    Edmonton, Alberta, T5H 0X5

  • Ivey Eye Institute

    London, Ontario, N6A 4V2

  • Retina Centre of Ottawa

    Ottawa, Ontario, K2B 7E9

Other trials in Canada

Czechia3 sites

  • Fakultní nemocnice Královské Vinohrady

    Prague, 100 34

  • Všeobecná fakultní nemocnice V Praze

    Prague, 128 08

  • Axon Clinical, s.r.o. Ocni Klinika

    Prague, 150 00

Other trials in Czechia

United Kingdom3 sites

  • Moorfields Eye Hospital NHS foundation Trust

    Greater London, London, EC1V 2PD

  • King's College Hospital

    London, SE5 9RS

  • The Retina Clinic London

    London, W1G 9AX

Other trials in United Kingdom

Austria2 sites

  • Klinikum Klagenfurt am Wörthersee

    Klagenfurt, 9020

  • Kepler Universitätsklinikum

    Linz, 4020

Other trials in Austria

New Zealand2 sites

  • Southern Eye Specialists

    Christchurch, Canterbury, 8013

  • Capital Eye Specialists

    Te Aro, Wellington Region, 6011

Other trials in New Zealand

Netherlands1 site

  • Elisabeth Hospital (ETZ) - location TweeSteden ziekenhuis

    Tilburg, 5042 AD

Other trials in Netherlands

About this study

Official title: A Phase 3, Multicenter, Randomized, Parallel-Group, Double-Masked, 2-Arm, Sham Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 (Vonaprument) Administered by Intravitreal Injection in Participants With Dry Age-Related Macular Degeneration With Geographic Atrophy

The primary purpose of the study is to determine if IVT injections of vonaprument every month reduce vision loss in participants with dry AMD with GA.

Being tested
Vonaprument, Sham Administration
Medical subject headings
Geographic Atrophy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • VonaprumentDrug

    Also called ANX007

    Form: solution for injection; Route of Administration: IVT injection

  • Sham AdministrationOther

    Form and Route of Administration: to mimic IVT injection (includes placement of the blunt opening of an empty, needleless syringe barrel on the conjunctiva in the inferotemporal quadrant of the eyeball to stimulate the pressure of an injection).

Study groups in NCT06510816
Study groupRoleWhat they receive
VonaprumentExperimentalParticipants will receive vonaprument IVT injections every month during the 24-month treatment period.
Receives: Drug: Vonaprument
Sham GroupSham comparatorParticipants will receive Sham IVT injections every month during the 24-month treatment period.
Receives: Other: Sham Administration

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Proportion of Participants Experiencing a Best Corrected Visual Acuity (BCVA) ≥15-letter Loss from Baseline Through Month 15 as Assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at Any Two Consecutive Visits

    Measured: Baseline through Month 15

  2. Proportion of Participants Experiencing a BCVA ≥15-letter Loss from Baseline Through Month 24 as Assessed by the ETDRS Chart at Any Two Consecutive Visits

    Measured: Baseline through Month 24

Secondary outcomes (3)

  1. Time to Confirmed BCVA ≥15-letter Loss

    Measured: Baseline to Month 15 and Baseline to Month 24

  2. Proportion of Participants with Low-luminance BCVA (LLVA) ≥15-letter Loss

    Measured: Baseline through Month 15 and Baseline through Month 24

  3. Change from Baseline in Area of Total Loss of the Ellipsoid Zone (EZ) Layer

    Measured: Baseline, Month 15 and 24

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Jul 2024
  2. Study start30 Jul 2024
  3. Primary completion31 Jul 2027 (estimated)
  4. Study completion31 Jul 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Double-masked
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
659 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06510816
Sponsor's protocol ID
ANX007-GA-02
Other IDs
2024-515022-88-00
Acronym
ARCHER II
Status last verified
Oct 2026
First submitted
15 Jul 2024
Last updated
6 Oct 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Vonaprument in people with Geographic Atrophy, run by Annexon, Inc. at 132 sites in 14 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 6 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 132 sites in United States, Spain, France, Italy, Australia and 9 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Proportion of Participants Experiencing a Best Corrected Visual Acuity (BCVA) ≥15-letter Loss from Baseline Through Month 15 as Assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at Any Two Consecutive Visits (time frame: Baseline through Month 15). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06510816.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in